# Effectiveness and Safety of Darunavir/Cobicistat Plus Lamivudine Versus Darunavir/Cobicistat Plus Tenofovir/Emtricitabine in Virologically Suppressed HIV-1-positive Individuals in Mexico

> **NCT06907056** · PHASE4 · RECRUITING · sponsor: **José Antonio Mata Marín** · enrollment: 138 (estimated)

## Conditions studied

- HIV Infection

## Interventions

- **DRUG:** dual therapy
- **DRUG:** Standard Medical Therapy

## Key facts

- **NCT ID:** NCT06907056
- **Lead sponsor:** José Antonio Mata Marín
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-11-09
- **Primary completion:** 2026-02-28
- **Final completion:** 2026-11-30
- **Target enrollment:** 138 (ESTIMATED)
- **Last updated:** 2025-04-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06907056

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06907056, "Effectiveness and Safety of Darunavir/Cobicistat Plus Lamivudine Versus Darunavir/Cobicistat Plus Tenofovir/Emtricitabine in Virologically Suppressed HIV-1-positive Individuals in Mexico". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06907056. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*